Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 3
2014 1
2015 4
2016 5
2017 4
2018 8
2019 6
2020 4
2021 1
2022 2
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Response to Biologic Drugs in Patients With Rheumatoid Arthritis and Antidrug Antibodies.
Bitoun S, Hässler S, Ternant D, Szely N, Gleizes A, Richez C, Soubrier M, Avouac J, Brocq O, Sellam J, de Vries N, Huizinga TWJ, Jury EC, Manson JJ, Mauri C, Matucci A, Hacein Bey Abina S, Mulleman D, Pallardy M, Broët P, Mariette X; ABIRISK Consortium. Bitoun S, et al. JAMA Netw Open. 2023 Jul 3;6(7):e2323098. doi: 10.1001/jamanetworkopen.2023.23098. JAMA Netw Open. 2023. PMID: 37436748 Free PMC article.
Longitudinal analysis of anti-drug antibody development in multiple sclerosis patients treated with interferon beta-1a (Rebif™) using B cell receptor repertoire analysis.
van der Weele L, Pollastro S, van Schaik BDC, van Kampen AHC, Niewold ITG, Kuijpers TW, Warnke C, Jensen PEH, Kramer D, Ryner M, Hermanrud C, Dönnes P, Pallardy M, Spindeldreher S, Deisenhammer F, Fogdell-Hahn A, de Vries N; ABIRISK Consortium. van der Weele L, et al. J Neuroimmunol. 2022 Sep 15;370:577932. doi: 10.1016/j.jneuroim.2022.577932. Epub 2022 Jul 14. J Neuroimmunol. 2022. PMID: 35853357 Free article.
Short report: Real-life analysis of the occurrence of persistent, transient, and fluctuating positive titres of neutralizing anti-drug antibodies in multiple sclerosis patients treated with interferon beta.
Oviedo Querejazu M, Dunn N, Ramanujam R, Ryner M, Auer M, Hyldgaard Jensen PE, Deisenhammer F, Fogdell-Hahn A; ABIRISK consortium. Oviedo Querejazu M, et al. Mult Scler Relat Disord. 2022 Jul;63:103815. doi: 10.1016/j.msard.2022.103815. Epub 2022 Apr 17. Mult Scler Relat Disord. 2022. PMID: 35508100
Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-beta: a GWAS.
Andlauer TFM, Link J, Martin D, Ryner M, Hermanrud C, Grummel V, Auer M, Hegen H, Aly L, Gasperi C, Knier B, Müller-Myhsok B, Jensen PEH, Sellebjerg F, Kockum I, Olsson T, Pallardy M, Spindeldreher S, Deisenhammer F, Fogdell-Hahn A, Hemmer B; ABIRISK consortium. Andlauer TFM, et al. BMC Med. 2020 Nov 4;18(1):298. doi: 10.1186/s12916-020-01769-6. BMC Med. 2020. PMID: 33143745 Free PMC article.
Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium.
Hässler S, Bachelet D, Duhaze J, Szely N, Gleizes A, Hacein-Bey Abina S, Aktas O, Auer M, Avouac J, Birchler M, Bouhnik Y, Brocq O, Buck-Martin D, Cadiot G, Carbonnel F, Chowers Y, Comabella M, Derfuss T, De Vries N, Donnellan N, Doukani A, Guger M, Hartung HP, Kubala Havrdova E, Hemmer B, Huizinga T, Ingenhoven K, Hyldgaard-Jensen PE, Jury EC, Khalil M, Kieseier B, Laurén A, Lindberg R, Loercher A, Maggi E, Manson J, Mauri C, Mohand Oumoussa B, Montalban X, Nachury M, Nytrova P, Richez C, Ryner M, Sellebjerg F, Sievers C, Sikkema D, Soubrier M, Tourdot S, Trang C, Vultaggio A, Warnke C, Spindeldreher S, Dönnes P, Hickling TP, Hincelin Mery A, Allez M, Deisenhammer F, Fogdell-Hahn A, Mariette X, Pallardy M, Broët P; ABIRISK consortium. Hässler S, et al. PLoS Med. 2020 Oct 30;17(10):e1003348. doi: 10.1371/journal.pmed.1003348. eCollection 2020 Oct. PLoS Med. 2020. PMID: 33125391 Free PMC article.
34 results